Sinopharm Group Co. Ltd. (SHTDF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sinopharm Group Co. Ltd. (SHTDF) trades at $2.30 with AI Score 45/100 (Grade C). Sinopharm Group Co. Ltd. Market cap: $7.18B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for SHTDF: SHTDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SHTDF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SHTDF: the 1 perspectives are evenly split.
How is this calculated? →Sinopharm Group Co. Ltd. (SHTDF) Healthcare & Pipeline Overview
Sinopharm Group Co. Ltd. is a prominent Chinese healthcare entity specializing in pharmaceutical and medical equipment distribution, supported by a vast retail pharmacy network of over 10,000 locations. The company also engages in manufacturing, logistics, and IT services, solidifying its comprehensive market position within the PRC's healthcare sector.
What Is the Investment Thesis for SHTDF?
Sinopharm Group Co. Ltd. (SHTDF) presents a unique investment profile within China's expansive healthcare sector, anchored by its substantial market capitalization of $7.18B and a P/E ratio of 6.35, which may suggest a potentially undervalued position relative to its earnings. The company's robust dividend yield of 4.35% offers an attractive income component for investors. Key value drivers include its deeply entrenched position in the Chinese pharmaceutical market, evidenced by an extensive distribution network that services hospitals, clinics, and other distributors, alongside a formidable retail presence of 10,259 pharmacy locations as of December 31, 2021. This integrated model provides broad market access and operational efficiencies. Growth catalysts are primarily driven by China's increasing healthcare expenditure, an aging population, and ongoing government initiatives to expand healthcare access and infrastructure. The company's strategic partnership with I-Mab is poised to enhance its commercial reach and market transformation efforts, potentially unlocking new revenue streams and efficiencies. Continued expansion of its retail pharmacy footprint and leveraging its comprehensive logistics capabilities are also significant growth avenues. However, investors must consider ongoing risks such as the evolving regulatory landscape in the Chinese pharmaceutical industry, which can impact pricing and market dynamics. Furthermore, its listing on the OTC Other market introduces liquidity risks, including potentially wider bid-ask spreads and challenges in trade execution, necessitating thorough due diligence.
Based on FMP financials and quantitative analysis
SHTDF Key Highlights
- Market Capitalization: $7.15 billion, indicating its substantial presence in the healthcare sector.
- P/E Ratio: 6.35, suggesting a potentially undervalued stock relative to earnings compared to broader market averages.
- Dividend Yield: 4.35%, offering income potential for investors.
- Extensive Retail Network: Operates 10,259 retail pharmacy locations as of December 31, 2021, demonstrating significant market penetration.
- Employee Base: Employs 108,217 individuals, highlighting its large operational scale.
Who Are SHTDF's Competitors?
SHTDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SHPMF Shanghai Pharmaceuticals Holding Co., Ltd | $1.46 | +0.00% | $8.46B | 45 |
| MSMKF MatsukiyoCocokara & Co. | $14.60 | +0.00% | $5.74B | 49 |
| SKHHY Sonic Healthcare Limited | $15.13 | +4.66% | $7.48B | — |
| GZPHF Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.34 | +0.00% | $6.20B | 43 |
| GNGBY Getinge AB (publ) | $21.24 | +0.80% | $5.78B | 47 |
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $100.89 | +1.33% | $293.21M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SHTDF's Key Strengths?
- Established and dominant market position within the Chinese healthcare sector.
- Extensive and efficient pharmaceutical and medical equipment distribution network.
- Large retail pharmacy footprint with 10,259 locations as of December 31, 2021.
- Diversified business segments including manufacturing, IT, and consulting services.
- Strategic partnership with I-Mab to enhance commercial reach and market transformation.
What Are SHTDF's Weaknesses?
- Relatively low profit margin of 1.2% compared to gross margin of 7.3%.
- Potential exposure to evolving regulatory changes within the Chinese pharmaceutical industry.
- Liquidity risks associated with its OTC Other listing, potentially affecting trade execution.
- Reliance on the Chinese domestic market for the majority of its operations and revenue.
What Could Drive SHTDF Stock Higher?
- Expansion of China's healthcare infrastructure and increasing government support for the sector.
- Increasing demand for pharmaceuticals and medical devices driven by an aging population and rising health awareness in China.
- Further leveraging the strategic partnership with I-Mab to enhance commercial reach and market transformation efforts.
- Potential for continued growth in its extensive retail pharmacy network beyond the 10,259 locations reported as of December 31, 2021.
What Are the Key Risks for SHTDF?
- Regulatory changes within the Chinese pharmaceutical industry, which can impact pricing, distribution, and market access.
- Liquidity risks associated with its OTC Other listing, potentially leading to wider bid-ask spreads and difficulty in executing trades.
- Intense competition from domestic and international players in the rapidly evolving Chinese healthcare market.
- Supply chain disruptions or economic downturns impacting the extensive distribution network and retail operations.
- Challenges in maintaining market share and adapting to new technologies or business models in the healthcare sector.
What Are the Growth Opportunities for SHTDF?
- **Expansion of Retail Pharmacy Network:** Sinopharm Group's existing network of 10,259 retail pharmacy locations as of December 31, 2021, provides a robust foundation for further expansion. The growing demand for convenient access to pharmaceuticals and health products in China presents a significant opportunity. By strategically opening new stores in underserved urban and rural areas, or through franchising, the company can capture a larger share of the fragmented retail pharmacy market. This expansion would leverage its established supply chain and brand recognition, enhancing direct-to-consumer sales and increasing market penetration over the next 3-5 years. The Chinese retail pharmacy market continues to grow, driven by an aging population and increasing health awareness, offering substantial long-term potential.
- **Enhanced Pharmaceutical Distribution and Logistics:** The company's core Pharmaceutical Distribution unit, which supplies hospitals, clinics, and other distributors, can capitalize on the increasing volume and complexity of pharmaceutical products entering the Chinese market. By investing in advanced logistics technologies, cold chain capabilities, and expanding its warehousing infrastructure, Sinopharm can offer more efficient and specialized distribution services. This would attract more domestic and international pharmaceutical manufacturers seeking reliable partners for market access and value-added services. The ongoing modernization of China's healthcare supply chain, projected to continue for the next decade, provides a fertile ground for Sinopharm to solidify its competitive advantage in this critical segment.
- **Strategic Partnerships and Market Transformation:** The strategic partnership with I-Mab to enhance commercial reach and market transformation efforts illustrates a proactive approach to growth. Sinopharm can pursue additional collaborations with innovative pharmaceutical and medical technology companies, both domestically and internationally. These partnerships could facilitate the introduction of new products, access to specialized therapeutic areas, or the adoption of advanced digital health solutions. Such alliances can accelerate market entry for novel treatments and expand Sinopharm's portfolio, positioning it favorably in high-growth segments. This strategy offers opportunities for revenue diversification and market share gains over a 2-5 year horizon.
- **Diversification into Specialized Medical Instruments and Traditional Chinese Medicine (TCM):** The "Other Business" segment already includes the trade of specialized medical instruments and traditional Chinese herbal medicines. With increasing focus on personalized medicine and preventative care, there is a growing market for specialized medical devices and a resurgence of interest in TCM both within China and globally. Sinopharm can strategically expand its offerings in these areas through targeted acquisitions, research and development, or enhanced distribution agreements. Capitalizing on its existing distribution channels, the company can become a leading provider in these niche but growing markets, potentially offering higher margin products over the medium to long term (5-10 years).
- **Digital Transformation and Information Technology Development:** Sinopharm's involvement in information technology development presents a significant growth opportunity in an increasingly digital healthcare landscape. By investing further in digital platforms for supply chain management, e-pharmacy services, telemedicine integration, and data analytics, the company can enhance operational efficiency, improve customer experience, and unlock new service offerings. Developing proprietary IT solutions can also create new revenue streams through licensing or service provision to other healthcare entities. The digitalization of healthcare in China is a multi-year trend, offering Sinopharm a chance to innovate and differentiate itself, optimizing its vast network and potentially reaching new customer segments through digital channels within the next 3-7 years.
What Opportunities Does SHTDF Have?
- Capitalize on the increasing healthcare demand driven by China's aging population and rising health awareness.
- Further expand its retail pharmacy network and enhance direct-to-consumer sales.
- Pursue strategic acquisitions or partnerships to broaden product portfolios and market segments.
- Leverage information technology development to improve logistics, e-pharmacy, and digital health services.
- Diversify into specialized medical instruments and traditional Chinese medicine markets.
What Threats Does SHTDF Face?
- Intense competition from both domestic and international players in the Chinese healthcare market.
- Ongoing evolution of regulatory policies and pricing controls in the pharmaceutical industry.
- Potential for supply chain disruptions or economic slowdowns impacting distribution and retail operations.
- Challenges related to maintaining market share against new entrants and innovative business models.
- Currency fluctuation risks given its operations in China and potential international dealings.
What Are SHTDF's Competitive Advantages?
- **Extensive Distribution Network:** A vast and deeply entrenched logistics and distribution infrastructure across China, providing unparalleled market reach.
- **Large Retail Footprint:** Operates over 10,000 retail pharmacy locations, offering direct consumer access and significant brand presence nationwide.
- **Integrated Business Model:** Diversified operations spanning wholesale distribution, retail, manufacturing, and various services create synergistic efficiencies and multiple revenue streams.
- **Strategic Partnerships:** Collaborations, such as with I-Mab, enhance commercial reach, market transformation capabilities, and access to innovative products.
- **Market Dominance in China:** A significant and established player in the large and growing Chinese healthcare market, benefiting from economies of scale and long-standing relationships.
What Does SHTDF Do?
Sinopharm Group Co. Ltd., established in 2003 and headquartered in Shanghai, China, operates as a significant entity within the People's Republic of China's healthcare sector. As a subsidiary of Sinopharm Industrial Investment Co., Ltd., the company has evolved into a comprehensive healthcare provider, primarily focusing on the wholesale and retail trade of pharmaceuticals, medical equipment, and a diverse range of health-related products. Its extensive operations are structured across four core divisions. The Pharmaceutical Distribution unit serves as a critical link in the supply chain, delivering a wide array of medicinal products to a broad client base, including hospitals, other distributors, retail pharmacies, and clinics throughout China. This segment is further enhanced by its provision of comprehensive distribution, logistics, and various value-added services for both domestic and international pharmaceutical and healthcare product manufacturers and suppliers, solidifying its role as a key facilitator in the market. The Medical Devices segment is dedicated to the efficient distribution of essential medical equipment, supporting healthcare providers with necessary tools and technologies. Complementing its wholesale activities, the Retail Pharmacy division manages and franchises a substantial network of drugstores, which had grown to 10,259 locations as of December 31, 2021, providing direct access to consumers nationwide. Beyond these primary areas, the company's "Other Business" segment is involved in the manufacturing and sale of pharmaceuticals, chemical reagents, and laboratory supplies, adding a vertical integration component to its operations. Sinopharm Group Co. Ltd.'s activities also encompass property leasing and management, the trade of specialized medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Furthermore, it invests in information technology development, offers a variety of consulting services (medicine, health, business, market information), engages in investment management, import and export, and provides convention and exhibition services. The company also manages medical project investments, consulting, and technology training initiatives, demonstrating a broad and integrated approach to the healthcare industry. A strategic partnership with I-Mab has been formed to further enhance its commercial reach and market transformation efforts, underscoring its commitment to continuous growth and adaptation within the dynamic Chinese market. The company employs a large workforce of 108,217 individuals, reflecting its significant operational scale.
What Products and Services Does SHTDF Offer?
- Wholesale distribution of pharmaceuticals to hospitals, clinics, and other distributors.
- Operate and franchise a large network of retail pharmacies across China.
- Distribute a wide range of medical equipment.
- Manufacture and sell pharmaceuticals, chemical reagents, and laboratory supplies.
- Provide comprehensive distribution, logistics, and value-added services for healthcare products.
- Engage in information technology development and various consulting services.
- Manage property leasing, investments, import/export, and convention services.
- Trade specialized medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products.
How Does SHTDF Make Money?
- Generates revenue from the wholesale and retail sales of pharmaceuticals, medical equipment, and health products.
- Earns income from operating and franchising its extensive network of 10,259 retail pharmacies.
- Derives revenue from manufacturing and selling pharmaceuticals, chemical reagents, and laboratory supplies through its 'Other Business' segment.
- Obtains fees for providing distribution, logistics, and value-added services to domestic and international healthcare product manufacturers.
- Engages in property leasing, IT development, consulting, and investment management activities.
What Industry Does SHTDF Operate In?
Sinopharm Group Co. Ltd. operates at the core of China's rapidly expanding healthcare industry, specifically within the medical distribution and retail pharmacy segments. The company is positioned as a dominant player in the wholesale and retail trade of pharmaceuticals, medical equipment, and health products across the People's Republic of China. The industry is characterized by robust growth, fueled by an aging population, rising disposable incomes, and increasing health awareness among Chinese citizens, alongside significant government investment in healthcare infrastructure. Sinopharm's extensive distribution network and its formidable retail pharmacy chain, comprising 10,259 locations as of December 31, 2021, provide a substantial competitive advantage in market penetration and last-mile delivery. While the market is competitive, with other major domestic and international players, Sinopharm's integrated business model, spanning distribution, retail, manufacturing, and value-added services, allows it to maintain a strong foothold. The company's strategic partnership with I-Mab further solidifies its positioning by enhancing commercial reach and market transformation capabilities in a dynamic and evolving landscape.
Who Are SHTDF's Key Customers?
- Hospitals, clinics, and other healthcare institutions throughout the People's Republic of China.
- Other pharmaceutical distributors and wholesalers within the healthcare supply chain.
- Individual consumers who purchase pharmaceuticals and health products from its retail pharmacy chain.
- Domestic and international pharmaceutical and healthcare product manufacturers utilizing its distribution services.
- Laboratories and research facilities requiring chemical reagents and laboratory supplies.
FY2026 estForward Outlook
Wall Street analysts project Sinopharm Group Co. Ltd. revenue of about $607.04B for fiscal 2026, with EPS near $2.47. The estimate reflects 11 contributing analysts.
SHTDF Valuation & Market Position
With a $7.18B market cap, Sinopharm Group Co. Ltd. sits in the mid-cap segment of the market. Relative to its peer group, SHTDF's quantitative score of 45/100 is roughly in line with the peer average of 46/100.
ROE 9%Key Financial Metrics
Return on equity for Sinopharm Group Co. Ltd. stands at 8.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.8%, showing how much profit it generates from its asset base. SHTDF trades at a trailing price-to-earnings ratio of 6.22, below the Healthcare sector average of ~23x. Its free cash flow yield is 23.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 16.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Sinopharm Group Co. Ltd.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.87 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Sinopharm Group Co. Ltd. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Wanyong Lian. SHTDF has traded publicly since 2011.
SHTDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established and dominant market position within the Chinese healthcare sector.
- Extensive and efficient pharmaceutical and medical equipment distribution network.
- Large retail pharmacy footprint with 10,259 locations as of December 31, 2021.
- Diversified business segments including manufacturing, IT, and consulting services.
Bear Case
- Relatively low profit margin of 1.2% compared to gross margin of 7.3%.
- Potential exposure to evolving regulatory changes within the Chinese pharmaceutical industry.
- Liquidity risks associated with its OTC Other listing, potentially affecting trade execution.
- Reliance on the Chinese domestic market for the majority of its operations and revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SHTDF Latest News
No recent news available for SHTDF.
SHTDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHTDF.
Price Targets
Wall Street price target analysis for SHTDF.
SHTDF MoonshotScore
What does this score mean?
The MoonshotScore rates SHTDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Wanyong Lian
Unknown
Wanyong Lian serves as the leader overseeing Sinopharm Group Co. Ltd.'s extensive operations, managing a substantial workforce of 108,217 employees. While specific details regarding their educational background, prior career history, or previous roles before joining Sinopharm are not provided in the available data, their current position indicates a significant leadership role within one of China's largest healthcare enterprises. The scope of their responsibilities encompasses the strategic direction and operational oversight of the company's diverse business segments, including pharmaceutical distribution, medical devices, retail pharmacies, and other manufacturing and service-related activities.
Track Record: Under Wanyong Lian's leadership, Sinopharm Group Co. Ltd. has maintained its prominent position in the Chinese healthcare sector, continuing to manage an expansive network of over 10,000 retail pharmacies and a broad distribution infrastructure. While specific achievements or strategic decisions directly attributable to their tenure are not detailed in the provided information, the company's sustained operational scale and its strategic partnership with I-Mab reflect ongoing efforts to enhance market presence and capabilities.
SHTDF OTC Market Information
Sinopharm Group Co. Ltd. (SHTDF) trades on the OTC Other tier of the OTC market. This tier is typically for companies that do not meet the disclosure requirements of higher OTC tiers like OTCQX or OTCQB, or major exchanges such as the NYSE or NASDAQ. Companies in the OTC Other tier may have limited public information available, and their financial reporting might not be as frequent or comprehensive as those on regulated exchanges. This classification indicates a lower level of transparency and regulatory oversight compared to companies listed on major U.S. exchanges, where stringent listing standards and reporting obligations are enforced to protect investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Lower trading volumes can make it difficult to enter or exit positions efficiently.
- Reduced Transparency: 'Unknown' disclosure status means less readily available or standardized financial and operational information.
- Price Volatility: Lower trading activity can lead to larger price swings on relatively small trading volumes.
- Regulatory Oversight: Less stringent regulatory requirements compared to major exchanges may expose investors to higher risks.
- Information Asymmetry: Investors may have less access to timely and comprehensive information, creating an uneven playing field.
- Verify the company's latest available financial statements and annual reports from official sources.
- Research the company's operational activities and market position within China's healthcare sector.
- Assess the management team's experience and track record, if additional information can be found.
- Examine any news or press releases from the company or reputable financial news outlets.
- Understand the regulatory environment in China pertaining to pharmaceutical distribution and retail.
- Evaluate the company's competitive landscape and its strategic partnerships.
- Consider the potential impact of foreign exchange rates on the company's financials.
- Substantial Market Capitalization: $7.15 billion indicates a large, established entity.
- Significant Employee Base: 108,217 employees suggests a large-scale, operational business.
- Established Founding Year: Founded in 2003, indicating a long operational history.
- Subsidiary of Sinopharm Industrial Investment Co., Ltd.: Suggests corporate backing and affiliation with a larger group.
- Strategic Partnership with I-Mab: Demonstrates ongoing business development and industry engagement.
Sinopharm Group Co. Ltd. Healthcare Stock: Key Questions Answered
What are Sinopharm Group Co. Ltd.'s primary business segments and their roles in the Chinese healthcare market?
Sinopharm Group Co. Ltd. operates through four main divisions, each playing a crucial role in the Chinese healthcare market. Its Pharmaceutical Distribution unit is central, supplying a vast array of medicinal products to hospitals, other distributors, retail pharmacies, and clinics across the country. This segment also offers comprehensive logistics and value-added services to manufacturers. The Medical Devices segment focuses on distributing essential medical equipment. The Retail Pharmacy division manages and franchises a network of 10,259 drugstores as of December 31, 2021, providing direct consumer access. Lastly, the Other Business segment encompasses manufacturing pharmaceuticals, chemical reagents, and laboratory supplies, along with diverse activities like property leasing, IT development, and consulting, creating an integrated presence across the healthcare value chain.
How does Sinopharm Group Co. Ltd. leverage its extensive distribution and retail network?
Sinopharm Group Co. Ltd. leverages its extensive distribution and retail network as a core competitive advantage within the Chinese healthcare market. The Pharmaceutical Distribution unit's broad reach ensures efficient delivery of medical products to a diverse client base, including hospitals and clinics, facilitating widespread market access for both domestic and international manufacturers. This network is further enhanced by its logistics capabilities and value-added services. Concurrently, the Retail Pharmacy division, with its 10,259 locations as of December 31, 2021, provides direct consumer touchpoints, enhancing brand visibility and capturing retail sales. This dual approach allows Sinopharm to serve both institutional and individual healthcare needs, optimizing supply chain efficiencies and solidifying its market penetration across the vast geographical landscape of China.
What are the implications of Sinopharm Group Co. Ltd.'s OTC Other listing for investors?
Sinopharm Group Co. Ltd.'s listing on the OTC Other tier carries several implications for investors. This tier typically has less stringent disclosure requirements compared to major exchanges like NYSE or NASDAQ, and even higher OTC tiers, leading to an "Unknown" disclosure status for SHTDF. This can result in less readily available or standardized financial and operational information, potentially increasing research complexity. Furthermore, OTC Other stocks often experience lower trading volumes and wider bid-ask spreads, which can lead to reduced liquidity. This means investors might find it more challenging to buy or sell shares quickly at desired prices, and the stock could be subject to higher price volatility due to fewer active participants in the market.
What strategic partnerships does Sinopharm Group Co. Ltd. have and how do they contribute to its operations?
Sinopharm Group Co. Ltd. has formed a strategic partnership with I-Mab, a collaboration designed to enhance its commercial reach and market transformation efforts. This partnership is crucial for Sinopharm as it allows the company to potentially expand its portfolio, access innovative products, or streamline its market entry strategies for new therapies. By collaborating with I-Mab, Sinopharm can leverage its vast distribution network and retail presence to bring new pharmaceutical products or services to the Chinese market more effectively. Such alliances are vital in the dynamic healthcare sector, enabling Sinopharm to adapt to evolving market demands, strengthen its competitive position, and potentially unlock new growth avenues beyond its organic capabilities, contributing to its long-term strategic objectives and operational efficiency.
What are the key factors to evaluate for SHTDF?
Sinopharm Group Co. Ltd. (SHTDF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does SHTDF data refresh on this page?
SHTDF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SHTDF's recent stock price performance?
Sinopharm Group Co. Ltd. (SHTDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established and dominant market position within the Chinese healthcare sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHTDF overvalued or undervalued right now?
Valuing Sinopharm Group Co. Ltd. (SHTDF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on the provided source data as of 2026-06-14. Specific details on CEO's title, background, track record, and OTC disclosure status were not fully available in the provided text and are noted as 'Unknown' or 'null' where applicable.